Evan Schauer

Evan Schauer began their work experience as a Graduate Student Researcher at UC Irvine from September 2009 to May 2011. Evan then moved on to work as a Laboratory Scientist at Amicrobe, Inc. from December 2011 to February 2013, where they focused on developing and testing formulations for novel peptide-based antimicrobial wound care, studying structure-function relationships in self-assembling polypeptides, and engineering formulations for increased efficacy, reduced toxicity, and lower costs.

In 2013, Evan joined Armata Pharmaceuticals, Inc. and held multiple roles within the company. Evan started as a Formulation Chemist, responsible for conducting formulation stability analysis of antimicrobial peptide C16G2 and developing and scaling up a gel formulation for C16G2 until December 2015. Evan then transitioned to an Associate Scientist position, where they worked until August 2019.

Their most recent role at Armata Pharmaceuticals, Inc. is as a Scientist in Process Development, starting in August 2019. In this role, Evan pioneers purification process development for bacteriophage in the Armata pipeline, with a focus on creating better and more scalable purification processes. Additionally, they have expertise in creating high-yield phage lyophilization processes.

Evan Schauer completed a Bachelor of Science degree in Chemical Engineering from UC Irvine, where they studied from 2005 to 2009. Following their undergraduate studies, they pursued a Master of Science degree in Materials and Manufacturing Technology at UC Irvine and graduated in 2011.